Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 06922 CRYOFOCUS-B > Detailed Quotes

06922 CRYOFOCUS-B

Watchlist
15.300
+0.320+2.14%
Closed  02/02 16:08 CCT
High
15.300
Open
15.300
Turnover
45.90K
Low
15.300
Pre Close
14.980
Volume
3.00K
Market Cap
3.66B
P/E(TTM)
Loss
52wk High
18.900
Shares
239.11M
P/E(Static)
Loss
52wk Low
13.000
Float Cap
1.75B
Bid/Ask %
33.33%
Historical High
18.900
Shs Float
114.10M
Volume Ratio
0.52
Historical Low
13.000
Dividend TTM
--
Div Yield TTM
--
P/B
25.42
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.00%
Amplitude
0.00%
Avg Price
15.300
Lot Size
200
Float Cap
1.75B
Bid/Ask %
33.33%
Historical High
18.900
Shs Float
114.10M
Volume Ratio
0.52
Historical Low
13.000
Dividend TTM
--
P/B
25.42
Dividend LFY
--
Turnover Ratio
0.00%
Amplitude
0.00%
Avg Price
15.300
Lot Size
200
Price Forecast

News

Comment

No Data

Company Overview More
Kangfeng Biotechnology (Shanghai) Co., Ltd. (formerly Kangfeng Biotechnology (Shanghai) Co., Ltd.) was founded in 2013 and is a leading cryomedical technology platform company with a unique advantage in the field of minimally invasive interventional cryotherapy. With unique liquid nitrogen cryoablation technology, the company is committed to building a comprehensive product portfolio, focusing mainly on two major treatment areas: (i) vascular intervention to treat major cardiovascular diseases, such as atrial fibrillation and high blood pressure, etc., and (ii) through natural channels to treat respiratory, urinary, and digestive diseases such as chronic obstructive pulmonary disease, asthma, airway stenosis, bladder cancer, stomach cancer, and esophageal cancer. The company's core team members have more than ten years of R&D experience and practical engineering application experience for medical device-related products. They specialize in cryo-ablation technology, and have successfully developed more than 10 pioneering international/domestic cryo-ablation products. They have obtained 105 patents, and 43 patents are being applied for. At present, the company has successfully developed a number of leading domestic or international cryoablation products, and is committed to making advanced cryoablation technology benefit a wide range of patients.
CEO: Kejian Li
Market: Hong Kong motherboard
Listing Date: 12/30/2022
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist